Brian Surratt spent 13 years working for the City of Seattle, including 2 1/2 leading the agency focused on the city’s economic development. In a new role he’s held for… Read More
Despite generics eating away at one of Bristol Myers Squibb’s highest sellers last year, Revlimid, CEO Giovanni Caforio maintained on Wednesday’s Q2 call that the company’s “foundation is strong” — and that he has all the tools necessary to keep building, including a fast-progressing late-stage pipe…
As interest grows in antibody drug conjugates, another small player is jumping into the space with sights set on an increasingly popular target. On Wednesday, Elevation Oncology licensed an ADC for gastric and pancreatic cancer from Chinese biotech CSPC Megalith Biopharmaceutical. The deal gives Ele…
Pennsylvania biotech Trevena put out word Thursday morning that it slashed 25% of its full-time staff and terminated a sales force agreement with Syneos, on top of a data readout it touted as positive. The biotech’s only approved product, marketed as Olinvyk, was OK’ed back in 2020 for moderate to
Senate Finance committee chair Ron Wyden (D-OR) on Wednesday sent follow-up letters to Merck and Abbott after both companies failed to answer questions and comply with his investigation into how a 2017 tax law helped slash tax rates for large, US-based pharma companies thanks to shifting profits off…
California-based biotech Synthego has been mainly focused on developing CRISPR-based tools to help researchers in academia and biotech, but its latest move now is turning its attention more towards manufacturing. The company has broken ground on a 20,000-square-foot manufacturing facility in the San…
Ionis put out positive topline results from a Phase IIb trial on end-stage renal disease, investigating patients on dialysis. The drug candidate, fesomersen, achieved its primary goal of
Sen. Joe Manchin (D-WV) once again found himself in the spotlight Wednesday evening, but this time his colleagues seem happy with the results. Manchin and Senate Majority leader Chuck Schumer (D-NY) struck a $740 billion reconciliation deal that will reduce the deficit by about $300 billion and now…
For the past decade, Daniel Nomura’s lab at UC Berkeley has been working to find chemical approaches to drug the so-called
As the issues from the Roe V. Wade decision continue to cascade in various circles, including the biotech world, one manufacturer is looking to push back against state law. According to a report from Bloomberg BNN, mifepristone manufacturer GenBioPro is looking to challenge a Mississippi anti-aborti…
Both Congressional Democrats and the pharma industry agree that pending drug pricing legislation is “historic” — they just diametrically disagree on the modifier. Trade industry group PhRMA’s CEO Stephen Ubl called it an “historic mistake” on Wednesday, joined by Eli Lilly CEO David Ricks, Atlas Ven…
As small molecule companies continue to get serious cash from investors as well as backing from major pharma companies such as Eli Lilly, California-based BridGene Biosciences is looking to stay ahead of the pack. The company announced Wednesday morning it pulled in a $38.5 million Series B, which w…
While Pfizer and BioNTech’s Covid-19 vaccine has been one of the primary treatments so far in the pandemic, both companies are still adjusting and making improvements amidst the spread of the Omicron variant and its subvariants. And now the latest step has come through. Both companies announced Wedn…
Just two weeks after the FDA again denied Lexicon Pharmaceuticals’ attempt to overturn a CRL in type 1 diabetes, the Texas biotech said the agency has accepted the drug’s resubmission for heart failure. A decision date is slated for sometime in May 2023. The regulator will consider two Phase III
Months after reports of allegations regarding Cassava Sciences’ lead drug candidate for Alzheimer’s emerged, the DOJ may now be raising its head to investigate the company. A report from Reuters published this morning said that two sources had confirmed the US Department of Justice opened an investi…
The growth of API manufacturing in India and China has led to numerous warning letters and lots of question marks around quality control and data integrity issues. But violations by US-based API manufacturers can be just as questionable. For instance, in a warning letter dated last week, St. Louis-b…
You can call it the summer of inception at Affini-T Therapeutics, the TCR upstart out of the Fred Hutch. Born with a trio of distinguished scientific godfathers, including Phil Greenberg. Backed by a pair of deep-pocket investors at Vida Ventures and Leaps by Bayer, won over by Affini-T’s swing-for-…
While drug pricing reform is snaking its way through Congress, the proposed legislation is facing some opposition from industry groups, as the National Association of Manufacturers is taking the fight to the airwaves. The trade group, the National Association of Manufacturers (NAM), has released a 3…
After its Covid-19 vaccine candidate petered out, CureVac earlier this month filed suit against BioNTech in German court, stating that CureVac should be compensated for the alleged infringement of a range of patents. However, BioNTech made clear that it is willing to go to the mat against CureVac, a…
Novartis may have suffered a setback in court over its blockbuster neuroscience drug Gilenya, but the pharma giant isn’t done fighting for it. A month after the US Court of Appeals for the Federal Circuit ruled 2-1 against Novartis in a patent infringement case, the Swiss pharma giant filed a